MTNB

Matinas Biopharma Holdings, Inc. is a clinical-stage biopharmaceutical company based in Bedminster, New Jersey, focused on developing novel pharmaceutical products. The company utilizes its proprietary Lipid Nano-Crystal (LNC) platform to enhance drug delivery, aiming to improve the safety, efficacy, and tolerability of therapies. Matinas is advancing drug candidates, including MAT2203, an oral formulation of amphotericin B for treating serious invasive fungal infections, with a Phase 3 registration trial planned. The company targets the fields of lipids and infectious diseases, collaborating with industry leaders to drive research and development.